相关实验视频

Updated: May 5, 2026

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

优化的脂质修饰原药用于中枢神经病毒治疗

Xinying Lv¹, Jingjing Shen¹, Xinwei Du²

¹Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, 215123, China.

Advanced materials (Deerfield Beach, Fla.)

|February 3, 2025

概括

新的脂质修饰原药,SU-C20纳米颗粒,显示出治疗胆道新血管化 (CNV) 的前景. 这些纳米颗粒可以改善药物保留和组织透,为湿性与年龄相关的黄斑变性 (wAMD) 提供潜在的替代疗法.

科学领域:

眼科医生眼科眼科
纳米医学是一种纳米医学.
药物输送系统药物输送系统

背景情况:

胆道新血管化 (CNV) 是视力丧失的主要原因之一.
目前的抗血管内皮生长因子治疗对CNV有局限性,包括不良的合规性,高成本和可变的疗效.
需要新的治疗策略来改善CNV的治疗结果.

研究的目的:

合成和评估SU5402 (SU) 的新型脂质修饰前药物,以改善抗新血管化作用.
使用聚乙烯醇 (PVA) 作为稳定剂,开发这些产药的纳米配方.
在临床前模型中评估这些纳米配方在治疗中枢肺炎中的疗效.

主要方法:

合成具有不同脂质链长度 (C12,C16,C20,C24,C28) 的SU5402前药物.
使用1%的PVA制备纳米配方 (NP).
在小鼠模型中评估药物保留,组织透性 (内细胞/外细胞) 和抗CNV疗效.

主要成果:

SU-C20 NPs在眼睛中显著延长药物保留时间 (长达70天).
SU-C20 NPs表现出增强的组织透性.
在CNV小鼠中,SU-C20NP减少了42.5%的 fundus泄漏强度和51.5%的面积,有效地抑制了CNV的进展.

结论:

将SU5402的脂质修饰转化为SU-C20NP代表了治疗底部神经血管疾病的有效策略.
SU-C20 NPs提供长时间的眼睛保留和改善组织透,增强治疗疗效.
这种方法提供了一个有前途的替代疗法,用于湿的与年龄相关的黄斑变性 (wAMD).

关键词:

抗血管生成的方法冠状腺新血管化冠状腺新血管化作为一种前药物,它是一种前药物.持续释放持续释放持续释放铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.